YZi Labs responds to CEA Industries' adoption of a "poison pill" plan and defensive charter amendments.

YZi Labs disclosed that it is reviewing CEA Industries' response to its written consent solicitation process, including actions such as employing a poison pill plan and amending the company's bylaws, aimed at thwarting and delaying shareholders' exercise of their rights. YZi Labs believes the board's actions are intended to consolidate its own position and that it has already postponed its 2025 annual meeting until after the anniversary date of December 17th. Furthermore, YZi Labs refuted CEA Industries' claim that it had never considered an alternative token strategy, pointing out that CEO David Namdar explicitly stated at an industry conference in November 2025 that they were considering a shift to assets such as Solana. YZi Labs urged the board to refrain from further actions and to ensure a fair nomination and election process for directors.